|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 10,981,952
U.S. Patent 10,981,952, granted on April 20, 2021, to Eli Lilly and Company, relates to a novel class of compounds and their use in treating neurodegenerative diseases, primarily Alzheimer’s disease. The patent claims cover both the chemical entities and their therapeutic applications.
Claims Overview:
-
Compound Claims: The patent claims a broad class of compounds characterized by a specific core structure, with variations in substituents (e.g., different alkyl, aryl groups). The structure primarily targets cholinesterase inhibition and potential neuroprotective effects.
-
Method Claims: The patent asserts methods of treating Alzheimer’s disease using these compounds, emphasizing oral administration and specific dosage regimes.
-
Use Claims: Claims extend to the use of compounds in manufacturing pharmaceutical preparations aimed at cognitive decline, memory impairment, and related neurodegenerative conditions.
-
Formulation Claims: Inclusive of pharmaceutical compositions—tablets, capsules, or solutions—containing the claimed compounds, with specified excipients.
Scope Analysis:
The patent's claims are broad within the chemical space, covering multiple derivatives of a core heterocyclic structure designed for central nervous system (CNS) activity. They also encompass various methods of administration and formulations to exploit the same chemical entities.
The scope enables the following:
-
Development of multiple therapeutic agents based on the claimed structural scaffold.
-
Patent protection not only for the chemical compounds but also for their therapeutic methods and pharmaceutical compositions.
-
Potential for follow-on research to optimize efficacy or reduce side effects, as the claims are directed at classes of compounds rather than a single entity.
Claims Limitations:
-
Specific substituents and structures are defined, but many claim features are broad, which may invite challenges based on inventive step or novelty.
-
The claims depend on particular chemical structures; compounds outside these structures may not be covered.
-
The patent does not explicitly claim combination therapies with other neurodegenerative treatment agents, which leaves room for separate patenting.
Patent Landscape Related to U.S. Patent 10,981,952
1. Parties and Filing Timeline
-
Filed: July 30, 2018, as a global application, with priority date claimed from a provisional application filed earlier in 2018.
-
Approval: Issued as a U.S. utility patent on April 20, 2021.
-
Assignee: Eli Lilly and Company, a major pharmaceutical innovator in CNS therapies.
2. Related Patent Families and Prior Art
-
Patent Families: The patent family includes applications in Europe (EP), Japan (JP), and Canada (CA), extending the global scope.
-
Prior Art: Includes multiple patents and scientific publications related to cholinesterase inhibitors and neuroprotective compounds. Key prior art references involve compounds such as donepezil, rivastigmine, and other heterocyclic cholinesterase inhibitors.
-
Novelty and Inventive Step: The patent differentiates by providing a new chemical scaffold with enhanced brain penetration and reduced peripheral side effects.
3. Competitor Patents in the Alzheimer’s & CNS Space
-
Other Approvals: Patents from companies like Novartis, Biogen, and AstraZeneca targeting similar mechanisms, such as NMDA receptor antagonists and beta-amyloid modulators.
-
Patent Overlaps: Some overlap with existing cholinesterase inhibitors, though the patent claims unique chemical modifications.
-
Trend: Increasing inclusion of multi-targeted compounds, combining cholinesterase inhibition with other mechanisms such as anti-aggregation.
4. Trends & Strategic Positioning
-
Growing focus on synthetic small molecules with improved pharmacokinetic and pharmacodynamic profiles.
-
Patent strategies involve broad claims on chemical classes coupled with narrow claims on specific derivatives.
-
Eli Lilly’s patent genome appears aimed at covering a wide chemical space, including potential follow-on compounds.
5. Patent Challenges & Litigation Risks
-
Known for potential challenges based on obviousness, especially given the similarity to prior cholinesterase inhibitors.
-
Patent validity may rely on demonstrating unexpected properties or improved safety profiles of specific compounds.
-
Patent enforcement could face hurdles if prior art is deemed to anticipate the broad claims.
Concluding Summary:
U.S. Patent 10,981,952 secures Eli Lilly’s novel compounds for Alzheimer’s disease with broad chemical and method claims. It fits into a landscape of existing CNS patents but differentiates based on structural novelty and potential therapeutic advantages. Competitors hold patents on similar mechanisms, creating a crowded patent environment for neurodegenerative therapeutics.
Key Takeaways
-
The patent covers a broad class of heterocyclic compounds intended for neurodegenerative disease treatment, primarily Alzheimer’s.
-
Claims include chemical entities, therapeutic methods, and pharmaceutical formulations with wide scope within the specified structural class.
-
The patent landscape includes multiple filings worldwide, with strategic claims aiming to prevent similar research around these compounds.
-
Challenges to patentability may originate from prior cholinesterase inhibitor patents, requiring patent owners to demonstrate unique advantages.
-
Continued innovation focuses on multi-mechanistic agents and improved pharmacokinetic profiles within the CNS space.
FAQs
-
What are the main chemical features protected by the patent?
The patent protects heterocyclic compounds with specific substituents designed for cholinesterase inhibition, with a core structure comprising certain nitrogen-containing rings.
-
How does this patent differ from existing Alzheimer’s drugs?
It covers a new chemical scaffold, potentially offering improved brain penetration, fewer peripheral side effects, or enhanced efficacy.
-
Does the patent extend to combination therapies?
No, claims primarily cover individual compounds, methods of use, and formulations. Combination therapy claims are not explicitly included.
-
Are the claims in the patent narrow or broad?
They are broad within the chemical class but rely on specific structural modifications, which could be challenged as obvious in light of prior art.
-
What are the potential legal risks for competitors?
Challenges could involve claims of obviousness and anticipation based on existing cholinesterase inhibitors; patent holders may enforce claims against infringing entities.
References
- U.S. Patent 10,981,952. Eli Lilly. "Cholinesterase inhibitors for neurodegenerative diseases." 2021.
More… ↓
⤷ Start Trial
|
